# A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults

## TL;DR

A Phase 1 trial tested a measles-based chikungunya vaccine in healthy adults, finding it safe and effective at higher doses with longer intervals.

## Contribution

The study demonstrated that a measles-vectored chikungunya vaccine is safe and immunogenic, with optimal dosing and interval strategies identified.

## Key findings

- The higher dose (5 × 105 TCID50) of MV-CHIK produced better antibody titers than the lower dose.
- Longer intervals between doses resulted in higher antibody titers in high-dose groups.
- The vaccine was well tolerated with mild to moderate side effects and no prolonged arthralgia.

## Abstract

This study of a measles-vectored vaccine for chikungunya virus (MV-CHIK) was a Phase 1 randomized, double-blinded, placebo-controlled trial with varying intervals between the 2 doses. The 6 cohorts each had 30 subjects, of which 25 received MV-CHIK and 5 received placebo. The 5 × 105 TCID50 dose was superior to the 5 × 104 TCID50 dose, and longer dosing intervals resulted in higher titers in the high dose groups. Mild to moderate injection site and systemic reactogenicity was common but brief. There was no evidence of prolonged vaccine-related arthralgia.

This Phase 1 clinical trial evaluated a measles-vectored chikungunya vaccine. The vaccine elicited good antibody titers and was well tolerated. Two doses of the higher titered vaccine and longer intervals between doses elicited the highest antibody titers.